LQDA
Liquidia Corporation NASDAQ$38.48
Mkt Cap $3.4B
52w Low $11.85
76.5% of range
52w High $46.67
50d MA $36.48
200d MA $30.85
P/E (TTM)
-47.7x
EV/EBITDA
-59.7x
P/B
73.3x
Debt/Equity
4.4x
ROE
-154.0%
P/FCF
-74.2x
RSI (14)
—
ATR (14)
—
Beta
0.46
50d MA
$36.48
200d MA
$30.85
Avg Volume
1.5M
About
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | 0.08 | 0.15 | +87.5% | 34.52 | +0.4% | +4.4% | +3.9% | +12.5% | +11.7% | +8.9% | +9.1% | — |
| Nov 3, 2025 | AMC | -0.45 | -0.04 | +91.1% | 25.22 | -1.9% | +10.7% | +4.8% | +1.5% | +3.4% | +8.1% | +33.8% | — |
| Aug 12, 2025 | AMC | -0.43 | -0.49 | -14.0% | 24.10 | +3.1% | +4.6% | +8.3% | +7.7% | +15.0% | +12.5% | +12.0% | — |
| May 8, 2025 | AMC | -0.42 | -0.45 | -7.1% | 15.35 | +1.2% | -0.6% | +2.6% | +4.2% | +21.5% | +25.7% | +17.4% | — |
| Mar 19, 2025 | AMC | -0.38 | -0.46 | -21.1% | 14.92 | -2.5% | +3.5% | +1.3% | +5.0% | +4.6% | -0.3% | -10.9% | — |
| Nov 13, 2024 | AMC | -0.37 | -0.37 | +0.0% | 10.27 | +0.4% | -2.3% | -4.2% | -4.4% | -1.1% | -1.5% | +6.3% | — |
| Aug 7, 2024 | AMC | -0.35 | -0.37 | -5.7% | 10.68 | +1.3% | +6.6% | +9.1% | +14.3% | +24.4% | +28.7% | -14.8% | — |
| May 13, 2024 | AMC | -0.32 | -0.54 | -68.8% | 12.14 | -1.6% | -1.5% | +1.2% | +4.9% | +4.7% | +10.0% | +9.7% | — |
| Mar 13, 2024 | AMC | -0.23 | -0.42 | -82.6% | 14.73 | +2.5% | +4.0% | +7.9% | +5.6% | +8.8% | +7.9% | -5.3% | — |
| Nov 7, 2023 | AMC | -0.20 | -0.24 | -20.0% | 6.80 | -1.3% | -4.5% | -9.9% | -7.8% | -7.0% | -6.2% | +5.9% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.63 | $9.64 | +0.1% | +3.5% | +2.1% | +0.2% | -0.9% | -0.9% |
| Aug 22 | Needham | Maintains | Buy → Buy | — | $9.98 | $9.97 | -0.1% | -3.5% | -0.1% | -1.5% | -3.3% | -4.4% |
| Aug 20 | BofA Securities | Maintains | Buy → Buy | — | $9.79 | $9.67 | -1.2% | -1.9% | +1.9% | -1.6% | +1.8% | +0.4% |
| Aug 20 | BTIG | Maintains | Buy → Buy | — | $9.79 | $9.67 | -1.2% | -1.9% | +1.9% | -1.6% | +1.8% | +0.4% |
| Aug 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.79 | $9.67 | -1.2% | -1.9% | +1.9% | -1.6% | +1.8% | +0.4% |
| Aug 19 | Raymond James | Upgrade | Outperform → Strong Buy | — | $14.11 | $8.95 | -36.6% | -30.6% | -32.0% | -29.3% | -31.8% | -29.3% |
| Aug 19 | BTIG | Maintains | Buy → Buy | — | $14.11 | $8.95 | -36.6% | -30.6% | -32.0% | -29.3% | -31.8% | -29.3% |
| Aug 19 | Needham | Maintains | Buy → Buy | — | $14.11 | $8.95 | -36.6% | -30.6% | -32.0% | -29.3% | -31.8% | -29.3% |
| Aug 13 | Needham | Maintains | Buy → Buy | — | $12.21 | $12.28 | +0.6% | +8.8% | +12.5% | +13.3% | +15.6% | -19.8% |
| Aug 8 | Needham | Maintains | Buy → Buy | — | $10.68 | $10.82 | +1.3% | +6.6% | +9.1% | +14.3% | +24.4% | +28.7% |
Recent Filings
Data updated apr 25, 2026 7:50pm
· Source: massive.com